Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hyaluronic Acid,Lidocaine
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Princess Volume Plus (hyaluronic acid) dermal filler and Lidocaine with the intention to confirm the efficacy and safety in respect of mid-facial volume insufficiency and/or mid-facial profile deficient participants.
Product Name : Princess Volume Plus
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2023
Lead Product(s) : Hyaluronic Acid,Lidocaine
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : China National Biotech Group
Deal Size : Undisclosed
Deal Type : Collaboration
Croma Establishes New Joint Venture in China
Details : The joint venture comprises Croma's Hyaluronic Acid Filler Princess® VOLUME and additional filler and facial aesthetic products and CNBG's multi-channel distribution, marketing experience and synergistic products, specifically its botulinum toxin produc...
Product Name : Princess Volume Plus
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 15, 2020
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : China National Biotech Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Croma’s botulinum toxin submission in Europe is based on 2 completed randomized, placebo-controlled Phase III pivotal trials (BLESS I and II) that enrolled a total of 917 subjects in Europe and the US.
Product Name : BoNT/A-DP
Product Type : Protein
Upfront Cash : Inapplicable
August 07, 2020
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable